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CC BY-NC-ND license (http://creativeAbstract Objective: To evaluate the efficacy of traditional Chinese herbs on heart failure
(HF) using nuclear magnetic resonance (NMR) metabolomics.
Methods: Plasma metabolomics was conducted on both patients with HF and healthy controls.
The partial least squares model was applied to determine potential metabolic markers and
related metabolic pathways of the disease. HF patients with the traditional Chinese syndrome
pattern of qi deficiency and blood stasis were divided into two groups, and treated, respec-
tively, with conventional medicine and a combination of conventional and Chinese herbs,
aimed at tonifying qi and activating blood. Healthy participants served as a control group
for comparison.
Results and conclusion: Both conventional and herbal treatments appear to regulate disorders
of amino acid and glucose metabolism. Combined treatment appears to be more comprehen-
sive, indicating that herbal and conventional medicines exert their effects through different
mechanisms in treating HF. It can be further inferred that herbs that tonify qi and activate
blood may regulate different essential metabolites.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Metabolomics, following genomics, transcriptomics, and
proteomics, has recently become an important component
of systems biology.1 Metabolomics considers the humandu.cn (W. Wang).
f Beijing University of Chinese Me
16.07.006
f Chinese Medicine. Production a
commons.org/licenses/by-nc-ndbody as a complete system, and physiologic and pathologic
reactions of the body to both internal and external factors
are revealed by changes in metabolism. This perspective
coincides with the holistic view and philosophy of tradi-
tional Chinese medicine (TCM).dicine.
nd hosting by Elsevier B.V. This is an open access article under the
/4.0/).
Evaluation of Chinese medicine 101Heart failure (HF) is the end stage of various heart dis-
eases. It is one of the most lethal cardiovascular diseases
threatening people’s health.2 As such, the medical profes-
sion is urgently challenged to address symptoms of this
disease and improves the quality of life of HF patients. In
China, traditional Chinese medicine (TCM) is often used to
treat HF as an adjunct to conventional therapies. For
example, a randomized controlled trial found the TCM
remedy Astragalus and Lepidium Capsule to Strengthen the
Heart (Qili Qiangxin Jiaonang) to be efficacious in treating
heart failure.3 However, further research on Chinese herbs
that treat HF can help elucidate their mechanism of action,
targets, and pathways. Metabolomics may be the key to
evaluating the efficacy of Chinese prescriptions through
tracking the pathologic metabolites and their changes
during treatment, and might serve as a new angle in
researching the mechanism of Chinese herbs. A major cause
of heart failure is coronary heart disease. Previously, our
group conducted a cross-sectional survey of 630 cases of HF
which was caused by coronary heart disease.4 TCM syn-
drome pattern identification varied from a single pattern to
a combination of six patterns, among which the combina-
tion of two or three patterns was most frequent, whereas a
single pattern was rare. Among patients with a single
pattern, qi deficiency occurred the most; among patients
with two patterns, qi deficiency and blood stasis were seen
most; among those with three patterns, a pattern of qi
deficiency, blood stasis, and water retention occurred most
frequently.
This current study was conducted using NMR metab-
olomics to explore the mechanisms of Chinese herbal
medicine in treating HF. Changes in metabolites were
analyzed to provide further information and reference.
Materials and methods
Participants
A total of 43 inpatients with heart failure from 12 hospitals
in China were included in the study. The 12 hospitals were:
TCM Hospital of Beijing Huairou (Beijing), Hepingli Hospital
(Beijing), Dongzhimen Hospital, Beijing University of Chi-
nese Medicine (Beijing), Xuanwu TCM Hospital (Beijing),
Changping Traditional Chinese Medicine Hospital (Beijing),
Changping Hospital of Integrated Chinese and Western
Medicine (Beijing), Dongfang Hospital, Beijing University of
Chinese Medicine (Beijing), Guang’anmen Hospital, China
Academy of Chinese Medical Sciences (Beijing), Zhengzhou
TCM Hospital (Zhengzhou, Henan), Affiliated Hospital of
Changchun University of Chinese Medicine (Changchun,
Jilin), Hubei Provincial Hospital of TCM (Wuhan, Hubei),
Wuhan Hospital of Traditional Chinese Medicine (Wuhan,
Hubei).
In addition, 25 healthy participants in the age-matched
control group were enrolled from Dongzhimen Hospital,
Beijing University of Chinese Medicine (Beijing).
Diagnostic criteria and TCM pattern identification
Diagnostic criteria were based on Guidelines for Diagnosis
and Treatment of Chronic Heart Failure in China (2007).5TCM pattern diagnosis of HF was based on Guiding Princi-
ples of Clinical Research on New Drugs in Treatment of
Heart Failure (Trial ), 2002 edition.6 HF was classified ac-
cording to the Criteria for Diagnosis and Treatment of Heart
Disease first published by the New York Heart Association
Functional Classification (NYHA).7
Inclusion and exclusion criteria
Patients were included in the study if they were diagnosed
with NYHA functional classification II or III (dyspnea, fa-
tigue, edema); were male or female between 40 and
80 years of age. In terms of TCM syndrome pattern, patients
had to have been diagnosed with qi deficiency, blood stasis,
and/or water retention for inclusion.
Patients were excluded if they had any of the following:
acute valvular heart disease, cardiomyopathy, pericardial
disease, congenital heart disease, acute myocardial
infarction within 4 weeks, acute myocarditis or serious
arrhythmia with variation in hemodynamics; pulmonary
arterial hypertension from cor pulmonale, pulmonary
embolism, or stroke within a half year; hepatic insuffi-
ciency (liver function 2 times normal), renal insufficiency;
hemopoietic diseases, malignancy, diabetes mellitus with
serious complications, thyroid disorders; infection, fever,
abnormal white blood cell counts; abnormal chest X-ray;
mental disorder; pregnant or lactating women; partici-
pated in other trials within 2 months. In terms of TCM
syndrome pattern, patients who did not present with qi
deficiency, blood stasis, and/or water retention were
excluded.
Ethical issues
This study was conducted according to the guidelines of
the Declaration of Helsinki and was approved by the Ethics
Committee of Dongfang Hospital, Beijing University of
Chinese Medicine (approval no. 201002102). All partici-
pants signed an informed consent form at the start of the
study.
Experimental design
A total of 43 patients were included in the study and were
randomly divided into 2 groups: combined treatment group
and conventional medicine group. SAS software version 8.1
(SAS Institute, Cary, NC, USA) was used to achieve
randomization. Twenty-three participants were assigned to
the combined herbal and conventional treatment, and 20
participants were assigned to conventional only treatment.
TCM herbal treatment consisted of herbs in granule form
to boost qi and activate the blood. The prescription was
formulated through data mining of herbs used for heart
failure of qi deficiency and blood stasis syndrome pattern,
and its efficacy had been demonstrated in a previous
study.8 Granules were dissolved in hot water and adminis-
tered twice a day, once in the morning and evening, with
28 days as a treatment course. Herbs in the formula were
astragalus root (Astragalus membranaceus (Fisch.) Bunge.),
60 g; codonopsis root (Codonopsis pilosula (Franch.)
Nannf.), 15 g; salvia root (Salviae miltiorrhizae Bunge.), 15
102 J. Chen et al.g; red peony root (Paeonia lactiflora Pall.), 15 g; peach
kernel (Prunus davidiana (Carr.) Franch.), 10 g; and saf-
flower (Carthamus tinctorius L.), 10 g.
Conventional treatment consisted of aldosterone,
other diuretics, angiotensin-converting enzyme inhibitors
(ACEIs), angiotensin receptor blockers (ARBs), beta
blockers, and digitalis. Administration and dosages of these
medicines were based stage of heart failure.
Healthy control participants received no interventions
and were not followed up. Blood samples were drawn from
each healthy control participant only on day 1 after
enrollment.
Blood sampling and preprocessing
Fasting blood (5 mL) was drawn from each HF participant in
the study on day 1 and day 28 after enrollment, and five
milliliters of fasting blood was drawn from each healthy
control participant only on day 1 after enrollment. The
samples were collected in EDTA-K3 anticoagulant tubes and
were centrifuged at 3694g for 15 min at room temperature.
The supernatant was collected and then frozen and stored
at 80C for later testing.
After thawing at room temperature, the blood samples
were centrifuged at 3958g for 5 min, and 200 mL of the
supernatant was drawn into a 1.5 mL EP tube. To this was
added 400 mL deuterium oxide (D2O; Cambridge Isotope
Laboratories, Tewksbury, MA, USA). The mixture was
shaken well and further centrifuged at 17,152g for 15 min
at 4C. Then 550 mL supernatant was collected into a 5 mm
NMR tube for later testing.
Nuclear magnetic resonance data collection
A nuclear magnetic resonance (NMR) system (Varian, Palo
Alto, CA, USA) was used to test the plasma samples by Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence, and the 1H
NMR spectrum was recorded. Water peak was suppressed by
presaturation. Saturation time was 2 s, mixing time was
0.1 s, spectral width was 12,000 Hz, sampling points were
64 k and cumulative frequency was 128. Both presaturation
frequency and center frequency lay on water peaks. One-
dimensional NMR spectrum was transformed from free in-
duction decay (FID) by 32 k Fourier transform infrared
spectroscopy (FTIR).
NMR data analysis
By using MestReNova software version 10.0.2 (Mestrelab,
Santiago de Compostela, Spain), correction of phasing and
baseline and peak alignment were conducted manually on
the 1H NMR spectrum, and calibration was performed
based on chemical shift on the NMR spectrum of lactate
methyl resonances (1.336 ppm). To reduce chemical
shift resulting from factors such as ionic strength and pH
value, and therefore to facilitate pattern recognition,
section integration was done by conduction on the spec-
trum by 0.01 ppm. Range of integration for CPMG was
0.5e9.0 ppm. A section of 4.68e5.20 m, 2.06e2.09 ppm,
2.53e2.59 ppm, 2.69e2.72 ppm, 3.07e3.22 ppm and
3.59e3.63 ppm on the spectrum was cut off to eliminatethe influence of water, D2O, EDTA and its metal complex
material on the chemical shift.9 Finally, the generated
data were normalized and standardized by centralization.
The processed data were further converted to Excel
format for pattern recognition.
Samples from all study groups were analyzed for
metabolome by SIMCA-P software version 11.0 (Umetrics,
Umea, Sweden). Data were then preprocessed by Pareto
scaling, and the principal components (PCs) were defined
by principal component analysis (PCA). Thus, differences
and similarities in plasma metabolism among groups could
be directly presented. Using the PCs, data on plasma
metabolic components were processed by partial least-
squares discriminant analysis (PLSDA), and PLSDA score
plots and loading plots of the samples were produced to
display the metabolite information of different samples
and identify characteristically different metabolites. Ac-
cording to NMR spectrum and chemical shift of VIP > 1,
and by using the compound database in the software
Chenomx NMR Suite version 8.12 (Chenomx, Emonton,
Alberta, Canada), different compounds in the spectrum
were determined. Effectiveness of the PLSDA model was
confirmed with Validate, a statistical validation. The cu-
mulative value of R2 and Q2 of 200 random arrangements
of Y variables and reconstruction of the PLSDA model were
calculated to test whether the model has statistical sig-
nificance. We also used online software, MetaboAnalyst
version 3.1 (Montreal, CA), to conduct cluster analysis for
an explanation of the internal laws of different metabo-
lites. This was followed by analysis of the metabolic
pathways of those metabolites.Statistical analysis
SPSS version 18.0 (IBM, Armonk, NY, USA) was used to
conduct statistical analysis of the comparison between
metabolite levels of participants with HF and the healthy
participants. After the test of normality and homogeneity
of variance, a t-test of independent samples and a rank
sum test were adopted for data analysis. Metabolic dif-
ferences among the data from the study groups before
and after treatment and those from the control group
were tested for normality and homogeneity of variance.
This was followed by ANOVA analysis of the data. All
statistical tests were performed using a two-tailed test,
and a P-value  .05 was considered statistically
significant.Results
Demographic characteristics of experimental
groups
Before treatment, the difference between the combined
treatment and conventional treatment groups showed no
significant differences in age, height, weight, sex, cardiac
function grades, comorbidities (hypertension, hyperlipid-
emia, and diabetes), medication (aldosterone, other di-
uretics, ACEIs/ARBs, beta blockers, and digitalis) and
treatment history (Table 1).
Table 1 Baseline values by treatment group.
Characteristics Combined
treatment
(n Z 23)
Conventional
medicine
(n Z 20)
P
Age (year) 68.9 (6.8)a 70.2 (8.4)a .354
Height (cm) 166.6 (7.4)a 165.5 (8.5)a .634
Weight (kg) 70.1 (9.9)a 69.6 (10.1)a .856
Sex (male/female) 13/10 11/9 .920
Cardiac function
grade (II/III)
5/18 5/15 .541
Hypertension n (%) 17 (73.9) 11 (55.0) .194
Hyperlipidemia n (%) 8 (34.8) 7 (35.0) .988
Diabetes n (%) 4 (17.4%) 5 (25.0) .711
Aldosterone n (%) 16 (73.9) 12 (60.0) .331
Other diuretics n (%) 20 (87.0) 13 (65.0) .148
ACEI/ARB n (%) 20 (87.0) 13 (65.0) .148
Beta inhibitor n (%) 20 (87.0) 14 (70.0) .263
Digitalis n (%) 11 (47.8) 7 (35.0) .395
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker.
a Values expressed as mean (SD).
Figure 2 PLSDA loading plots of HF groups and healthy
controls.
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control group
NMR pattern recognition
Based on the PLS score plot, the data of HF participants and
those of the control group can be separated, to a great
degree, along the axial direction of t1 with no overlapping
among nodes (Fig. 1). As shown on the score plot, data for
HF participants and those for the control group can be
easily distinguished, indicating the presence of significant
differences in the plasma metabolic profile. R2X, R2Y, and
Q2 are key indicators of the PLSDA model quality. R2X shows
the explanation rate of the model, summarizing X matrices;
R2Y reflects stability; Q2 represents predictability. Thus,
the closer to 1 R2Y and Q2 are, the more stable andFigure 1 PLSDA score plots of HF groups (red circles) and
healthy controls (black squares).predictable the model is. In this study, R2X Z 0.139,
R2Y Z 0.826, and Q2 Z 0.729, indicating that the estab-
lished model can accurately and reliably distinguish HF
participants from healthy participants. The corresponding
load diagram of the PLS model reveals a contribution ratio
of different metabolites in distinguishing HF participants
from healthy participants, in which the longer the distance
from the origin indicates a larger contribution (Fig. 2). The
result of PLSDA’s Validate shows an intersecting trend of
lines R2 and Q2, which can be considered as evidence of
effectiveness of the PLSDA model (Fig. 3).
VIP score analysis
Based on the VIP score of the PLSDA model derived from the
CPMG test and by application of Chenomx NMR Suite, we
found 27 metabolites whose VIP scores were greater than 1.Figure 3 Statistical validation of the PLSDA model, showing
R2 (green triangles) and Q2 (blue squares) values from the
permuted analysis (bottom left) significantly lower than the
corresponding original values (top right).
Figure 4 VIP scores of the variables. Top 15 significant fea-
tures of the metabolite markers are based on the VIP scores:
0 Z healthy controls; 1 Z HF participants.
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the load diagram, and their contribution ratios were high.
Moreover, we conducted a t-test or non-parametric tests on
these metabolites. Result showed that compared to the
control group, the data of 21 metabolites from the HF
participants were statistically significant (P < .05) (Table
2). Compared with the same 21 metabolites from the con-
trol group, HF participants had elevated levels of isoleu-
cine, 3-hydroxyisobutyrate, lactate, alanine, glycylproline,
methionine, citrate, sarcosine, proline, fructose, creati-
nine, choline, 3-methylhistidine, and phenylalanine and
decreased levels of valine, threonine, glutamate, gluta-
mine, b-glucose, a-glucose, and glycine. The 15 most sig-
nificant features of metabolite markers in distinguishing HF
patients from healthy participants are shown in Fig. 4.
These metabolites were determined based on VIP scores
and processed by MetaboAnalyst 3.1.
Metabolic pathway analysis
Based on the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database, MetaboAnalyst 3.1 was applied to help
determine the most relevant metabolic pathways in our
research. These metabolites participate in the pathologic
process of HF mainly by means of amino acid and glucoseTable 2 Metabolites associated with HF.
No. Metabolite Chemical shift (ppm) VIP Pathway
1 Isoleucine 0.94, 0.95 1.13 Unknown
2 Valine 0.99e1.01 2.14 Valine, leucine, and isoleucine metabolism/propanoate
metabolism
3 3-Hydroxyisobutyrate 1.06, 1.08 1.27 Valine, leucine, and isoleucine degradation
4 Lactate 1.33, 4.08e4.12 1.52 Glycolysis or gluconeogenesis/propanoate metabolism
5 Threonine 4.25e4.27 1.16 Glycine, serine, and threonine metabolism/valine, leucine and
isoleucine biosynthesis/pantothenate and CoA biosynthesis/
porphyrin and chlorophyll metabolism
6 Alanine 1.47e1.49 1.71 Cyanoamino acid metabolism
7 Glycylproline 1.84, 1.86 1.17 Unknown
8 Glutamate 2.15, 2.36 3.08 D-glutamine and D-glutamate metabolism/nitrogen metabolism
9 Methionine 2.64 1.22 Unknown
10 Glutamine 2.46e2.50, 3.77 2.27 D-glutamine and D-glutamate metabolism/nitrogen
metabolism/arginine and proline metabolism/purine
metabolism/alanine, aspartate and glutamate metabolism
11 Citrate 2.67, 2.68 1.79 Citrate cycle (TCA cycle)
12 Sarcosine 2.74 1.92 Glycine, serine, and threonine metabolism/arginine and
proline metabolism
13 Proline 3.32e3.34 1.89 Arginine and proline metabolism
14 b-Glucose 3.36, 3.37 2.96 Glycolysis or gluconeogenesis/starch and sucrose metabolism/
pentose phosphate pathway
15 a-Glucose 3.44, 3.73, 3.75, 3.83 1.45 Glycolysis or gluconeogenesis/starch and sucrose metabolism/
amino sugar and nucleotide sugar metabolism
16 Glycine 3.56, 3.57 2.06 Glycine, serine, and threonine metabolism/cyanoamino acid
metabolism/thiamine metabolism/purine metabolism/
porphyrin and chlorophyll metabolism
17 Fructose 3.65, 4.02, 4.13 1.52 Starch and sucrose metabolism/amino sugar and nucleotide
sugar metabolism
18 Creatinine 4.05, 4.06 1.45 Arginine and proline metabolism
19 Choline 4.07 1.70 Glycine, serine, and threonine metabolism
20 3-Methylhistidine 7.05, 7.75, 7.76 3.38 Unknown
21 Phenylalanine 7.42 1.18 Nitrogen metabolism/phenylalanine, tyrosine, and tryptophan
biosynthesis
Evaluation of Chinese medicine 105metabolism (Table 2). Among them, glycine, serine, and
threonine metabolism had higher scores, and their meta-
bolic pathways are shown in Fig. 5.Effect of combined treatment on metabolism in HF
participants
NMR pattern recognition
The PLSDA model showed clear separation of the results of
the group undergoing combined treatment before and after
treatment and that of the control group, indicating the
presence of significant differences in the plasma metabolic
profile (Fig. 6). The results were R2XZ 0.172, R2YZ 0.702
and Q2 Z 0.554, from which it can be inferred that the
established model can reliably distinguish between patients
before and after the treatment and those from the controlFigure 5 Glycine, serine, and threonine metabolism pathways in
kegg).group. Validated results of the PLSDA displayed trend of
intersecting lines of R2 and Q2, which may be considered as
evidence of effectiveness of the PLSDA model (Fig. 7).
VIP score analysis
ANOVA and Bonferroni10 tests were conducted on the peaks
of the chemical shifts of 27 metabolites whose VIP scores
were greater than 1. Of the 27 metabolites, 22 were sta-
tistically significant (P < .05) among the three groups of
data. The results of multiple comparisons showed that
levels of 3-hydroxyisobutyrate, lactate, glycylproline,
methionine, b-glucose, a-glucose, fructose, 3-
methylhistidine, and phenylalanine after treatment in the
combined therapy group did not differ significantly (P> .05)
from levels in the control group. However, levels of lactate,
fructose, and phenylalanine did differ markedly (P < .05)
before and after treatment (Table 3).humans. The map was generated using KEGG (www.genome.jp/
Figure 6 PLSDA score plots of combined treatment group
(before treatment, red circles; after treatment, blue di-
amonds) and healthy controls (black squares).
Figure 7 Statistical validation of the PLSDA model. A per-
mutation test performed with 200 random permutations in a
PLSDA model showing R2 (green triangles) and Q2 (blue boxes)
values from the permuted analysis (bottom left) significantly
lower than the corresponding original values (top right).
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HF participants
NMP pattern recognition
PLSDA showed clear separation of the results of the con-
ventional medicine group before and after the treatment
and that of the control group, indicating significant differ-
ences in the plasma metabolic profile (R2X Z 0.166,
R2Y Z 0.728 and Q2 Z 0.518) (Fig. 8). From the results it
can be inferred that the established model can reliably
distinguish between patients before and after the treat-
ment from the healthy control group. Validated results of
the PLSDA showed an intersecting trend of lines of R2 andQ2 as evidence of the effectiveness of the PLSDA model
(Fig. 9).
VIP score analysis
ANOVA and Bonferroni tests were conducted on the peaks
of chemical shifts of 27 metabolites whose VIP scores were
greater than 1. Of the 27 metabolites, 22 were statistically
significant (P < .05) among the three groups of data. Mul-
tiple comparisons indicated that levels of lactate, glycyl-
proline, b-glucose, a-glucose, and phenylalanine from after
treatment of the conventional medicine group and from the
control group were not statistically different (P > .05).
However, b-glucose levels before and after treatment in
the conventional medicine group was significant (P < .05)
(Table 4).
Comparison of combined treatment and
conventional treatment on HF
After combined treatment, 9 of 22 metabolites in HF par-
ticipants returned to levels of the control group, and
changes in 3 of the 22 metabolites were significant
compared to pre-treatment. In the group that received
conventional treatment, 5 of 22 metabolites in HF partici-
pants returned to levels of the control group, and changes
in 1 of the 22 metabolites were marked compared to pre-
treatment.
Discussion
In this study, we applied metabolomics to investigate
changes in various metabolites in heart failure patients as
compared to healthy persons who served as controls. Me-
tabolites were identified that can be used as diagnostic
biomarkers. Metabolite biomarkers associated with energy/
amino acid metabolism are threonine, proline, sarcosine,
glutamate, glutamine, isoleucine, valine, alanine, glycine,
phenylalanine, 3-methylhistidine, glycylproline and methi-
onine. Metabolite biomarkers associated with glucose
metabolism are lactate, creatinine, b-glucose, a-glucose,
and fructose, and with the citric acid cycle, citrate, and
with lipid metabolism, 3-hydroxyisobutyrate and choline.
In terms of metabolism of amino acids, proline is a major
component of collagen, which makes up part of the
composition of atherosclerotic plaques11 and an elevated
level of serum collagen may indicate progression of HF.
Glutamine is involved in various metabolic pathways and in
regulating the homeostasis of amino acids.12 Glutamine is
synthesized in the body by glutamic acid, valine, and
isoleucine, and decreased levels of glutamine and gluta-
mate in the plasma of HF patients are indicative of immune
function decline, disorder in amino acid metabolism, and
subsequent abnormal levels of valine and isoleucine. The
main metabolic pathway of threonine is conversion into
glycine, whose increase is related to its protection of
ischemic cells. Increase in 3-methylhistidine, produced by
histidine and methyl transferred from S-adenosyl-methio-
nine, reflects an increase in the breakdown rate of muscle
protein. Phenylalanine can be converted into catechol-
amines, and its elevated level is associated with increased
nerve excitability in HF.13
Table 3 ANOVA results for combined treatment group (before and after treatment) and the control group.
Metabolites After combined treatment
(n Z 23)
Before combined treatment
(n Z 23)
Control group
(n Z 25)
P
Isoleucine 0.162  0.038 0.171  0.051# 0.204  0.032* .001
Valine 0.125  0.037 0.139  0.055# 0.208  0.044* .001
3-Hydroxyisobutyrate 0.018  0.006 0.022  0.007# 0.013  0.007 .001
Lactate 0.032  0.011 0.045  0.020*# 0.028  0.011 .001
Threonine 0.023  0.010 0.030  0.008# 0.041  0.013* .001
Alanine 0.438  0.352 0.521  0.371# 0.120  0.033* .001
Glycylproline 0.017  0.011 0.019  0.009# 0.010  0.008 .007
Glutamate 0.142  0.084 0.145  0.091# 0.316  0.052* .001
Methionine 0.020  0.009 0.025  0.013# 0.013  0.006 .001
Glutamine 0.683  0.108 0.662  0.115# 0.853  0.100* .001
Citrate 0.014  0.008 0.016  0.006# 0.006  0.005* .001
Sarcosine 0.048  0.019 0.046  0.015# 0.020  0.006* .001
Creatine 0.089  0.040 0.117  0.043# 0.160  0.054* .001
b-Glucose 2.034  0.300 1.836  0.494# 2.119  0.204 .043
a-Glucose 0.696  0.102 0.629  0.111# 0.722  0.084 .007
Proline 0.073  0.029 0.075  0.028# 0.050  0.014* .001
Glycine 0.215  0.066 0.208  0.084# 0.341  0.076* .001
Fructose 0.024  0 .009 0.037  0.016*# 0.026  0.007 .007
Creatinine 0.142  0.070 0.148  0.062# 0.100  0.025* .001
Choline 0.074  0.020 0.075  0.026# 0.047  0.013* .001
3-Methylhistidine 0.008  0.020 0.012  0.015# 0.002  0.005 .001
Phenylalanine 0.001  0.005 0.002  0.002*# 0.001  0.005 .002
*Compared with after combined treatment, P < .05; #Compared with healthy controls, P < .05.
Figure 8 PLSDA score plots of conventional medicine group
(before treatment, red circles; after treatment, blue di-
amonds) and healthy controls (black squares).
Evaluation of Chinese medicine 107This study found a decrease in plasma glucose in HF
patients caused by coronary heart disease, a finding
consistent with research by others.14,15 The primary
biochemical effect of creatine and sarcosine is to form a
creatineephosphocreatine energy transfer system; thus,
adenosine triphosphate (ATP) can be supplemented by
means of phosphocreatine. Therefore, in myocardial
ischemia, additional energy can be provided to themyocardium by increasing creatine and creatinine.16
Under anaerobic conditions, glucose turns into lactic
acid through glycolysis, whereas under normal physiologic
conditions this process does not function as a major supply
of energy. However, with strenuous exercise or tissue
hypoxia, energy supply is inadequate and inhibition in
aerobic oxidation ensues. Consequently, production of
ATP decreases, and glycolysis is enhanced. Further, if
there is a decline in liver and kidney function, lactic acid
can accumulate. Therefore, tissue hypoxia in HF can lead
to an elevated level of plasma lactate. Accumulation of
lactic acid and an increased level of pyruvic acid lead to
an elevated level of alanine as produced by pyruvate
transamination.
The tricarboxylic acid cycle is the final pathway and
intersection of carbohydrate, lipid, and amino acid meta-
bolism, with citric acid an intermediate metabolite of the
process. In our study, compared with healthy controls, HF
patients had elevated levels of plasma citric acid, indi-
cating that inhibition in the tricarboxylic acid cycle causes
reduced energy production.
With lipid metabolism, oxidation of fatty acids involves
3-hydroxyisobutyrate and choline. In HF, tissue hypoxia
causes enhancement of fatty acid oxidation, which results
in the increase of 3-hydroxyisobutyrate and choline in
plasma.
Thus, in chronic myocardial ischemia, disorders in amino
acid metabolism, glucose metabolism, tricarboxylic acid
cycle, and lipid metabolism are the main pathologic
mechanisms in the onset of HF and its progression. Further,
these metabolites may serve as potential biomarkers and
therapeutic targets of the disease.
Figure 9 Statistical validation of the PLSDA model. A per-
mutation test performed with 200 random permutations in a
PLSDA model showing R2 (green triangles) and Q2 (blue boxes)
values from the permuted analysis (bottom left) significantly
lower than the corresponding original values (top right).
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Their effect in formulations consisting of more than one
herb is likely synergistic, and different biologic pathways
are probably targeted. Metabolomics can not only evaluate
the efficacy of Chinese herbs but also reveal endogenous
changes of metabolites. In recent years, metabolomics is
being heavily applied to investigate the mechanism ofTable 4 ANOVA results for conventional medicine group (befor
Metabolites After conventional treatment
(n Z 20)
Be
(n
Isoleucine 0.147  0.042 0.
Valine 0.116  0.039 0.
3-Hydroxyisobutyrate 0.073  0.055 0.
Lactate 0.541  0.190 0.
Threonine 0.026  0.010 0.
Alanine 0.383  0.278 0.
Glycylproline 0.018  0.016 0.
Glutamate 0.128  0.055 0.
Methionine 0.027  0.012 0.
Glutamine 0.691  0.080 0.
Citrate 0.013  0.010 0.
Sarcosine 0.048  0.019 0.
Creatine 0.100  0.033 0.
b-Glucose 0.361  0.103 0.
a-Glucose 1.120  0.128 1.
Proline 0.078  0.038 0.
Glycine 0.209  0.079 0.
Fructose 0.508  0.154 0.
Creatinine 0.152  0.053 0.
Choline 0.081  0.034 0.
3-Methylhistidine 0.029  0.028 0.
Phenylalanine 0.000  0.009 0.
*Compared with after treatment with conventional medicine, P < .05Chinese herbs, in particular classical formulas, in various
disorders.17e19 Thus, the material basis of their actions can
be better explained and their mechanisms inferred from
their therapeutic effects.
In this study, PLSDA score plots of the experimental
groups displayed a shift toward that of the control
group, suggesting that metabolic pathways were
restored. Both combined treatment and conventional
treatment appeared to restore metabolism of amino
acid, glucose, lipid, and tricarboxylic acid cycles, in
particular metabolism of amino acids and glucose in
HF patients. Comparison of the results from the two
experimental groups revealed that after combined
treatment, 9 of 22 metabolites in the HF patients
returned to healthy levels, and changes in 3 of the 22
metabolites were significant compared to pre-treatment.
Thus, combined treatment appears to restore the meta-
bolism of amino acids (phenylalanine, glycylproline, 3-
methylhistidine, and methionine), glucose (lactate, b-
glucose, a-glucose, and fructose), and lipids (3-
hydroxyisobutyrate) in HF patients. In the group that
received conventional treatment, only 5 of 22 metabo-
lites in the HF patients returned to normal, and changes
in only 1 of the 22 metabolites were marked compared to
pre-treatment. Therefore, conventional treatment ap-
pears to restore metabolism of amino acids (phenylala-
nine and glycylproline) and glucose (lactate, b-glucose
and a-glucose) in HF patients. Compared to conventional
medicine, combined treatment exerts a more compre-
hensive regulation of metabolic pathways, suggesting that
the mechanism of action of Chinese herbs differs from
that of conventional medicine.e and after treatment) and the control group.
fore conventional treatment
Z 20)
Control group
(n Z 25)
P
157  0.050# 0.204  0.032* .001
116  0.027# 0.208  0.044* .001
055  0.032# 0.278  0.083* .001
576  0.331# 0.391  0.120 .003
031  0.014# 0.041  0.013* .001
410  0.285# 0.120  0.033* .001
023  0.013# 0.010  0.008 .002
098  0.038# 0.316  0.052* .001
026  0.013# 0.056  0.019* .001
639  0.088# 0.853  0.100* .001
018  0.011# 0.006  0.005* .001
043  0.016# 0.020  0.006* .001
115  0.050# 0.160  0.054* .001
472  0.157*# 0.297  0.082 .001
055  0.156# 1.184  0.074 .003
080  0.047# 0.050  0.014* .001
229  0.137# 0.341  0.076* .001
524  0.172# 0.390  0.057* .002
157  0.058# 0.100  0.025* .001
084  0.033# 0.047  0.013* .001
028  0.027# 0.005  0.004* .001
005  0.009# 0.001  0.004 .039
; #Compared with healthy controls, P < .05.
Evaluation of Chinese medicine 109This study also showed that the efficacy of the Chinese
herbs in the prescription that we used to boost qi and
activate the blood, might be found in the difference be-
tween the results of the two experimental groups at the
pathways of four metabolites: 3-methylhistidine, methio-
nine, fructose, and 3-hydroxyisobutyrate. Combined usage
of Chinese and Western medicine in cases of HF can
enhance efficacy, which highlights advantages of TCM in
alleviating symptoms and improving the quality of life for
HF patients.
Conclusion
This study used NMR metabolomics to evaluate the effect of
Chinese herbal medicine on heart failure. Results suggest
that 21 metabolic markers may be related to the meta-
bolism of amino acids, glucose, and lipids as well as the
tricarboxylic acid cycle. Moreover, herbs that tonify qi and
activate blood may exert their effects by regulating the
pathways of some of the aforementioned metabolites. This
study provides a scientific evaluation of the efficacy of TCM
prescriptions that treat heart failure.
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